A carregar...
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
Drug combination trials are increasingly common nowadays in clinical research. However, very few methods have been developed to consider toxicity attributions in the dose escalation process. We are motivated by a trial in which the clinician is able to identify certain toxicities that can be attribu...
Na minha lista:
| Publicado no: | Biom J |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6261712/ https://ncbi.nlm.nih.gov/pubmed/29808507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201700166 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|